Table 1. Clinical and laboratory features of the whole study group, and comparative analysis of group A (COVID-19-era) and group B (control).
Group A: patients in the COVID-19 era. Group B: a control group of patients in the registry before the COVID-19 era.
| Clinical data | Group A | Group B | P value |
|---|---|---|---|
| (n: 30) | (n: 398) | ||
| Age (years) | 37 [28–46] | 30 [23–39] | 0.01 |
| Male gender | 19 (63.3%) | 243 (61.1%) | 0.81 |
| Time from IE-symptoms to consideration of diagnosis (days) | 60 [31–92] | 28 [14–72] | 0.007 |
| Fever as a presenting symptom | 26 (86.7%) | 335 (84.2%) | 1.0 |
| Injecting IV drugs | 6 (20.0%) | 42 (10.6%) | 0.13 |
| Structural heart predisposition | 14 (46.7%) | 255 (64.1%) | 0.057 |
| Prosthetic valve | 6 (20%) | 104 (26.1%) | 0.46 |
| Procedures in the last 3 months | 3 (10%) | 95 (23.9%) | 0.08 |
| Prior Endocarditis | 3(10%) | 15(3.8%) | 0.12 |
| Temperature on admission (°C) | 39 [38–39] | 38 [38–39] | 0.003 |
| Laboratory data | |||
| Culture-negative IE | 15 (50%) | 275 (69.1%) | 0.031 |
| Hb on admission (g/dl) | 8.8 (8.0–11) | 9.5 (8.0–11.0) | 0.31 |
| Hb lowest level (g/dl) | 9.6 (8.4–10.6) | 8.9 (7.3–10.5) | 0.72 |
| Hb on discharge (g/dl) | 9.7 (8.5–11.0) | 10.3 (9.0–11.2) | 0.07 |
| Cr on admission (mg/dl) | 1.0 (0.8–1.1) | 0.9 (0.7–1.3) | 0.32 |
| Maximum Cr (mg/dl) | 1.2 (0.98–1.6) | 1.6 (0.96–2.8) | 0.15 |
| Cr on discharge (mg/dl) | 0.8 (0.8–1.0) | 1.0 (0.7–1.4) | 0.35 |
| Baseline ESR | 115 (82–120) | 100 (60-120) | 0.12 |
| Final ESR | 20 (20–32) | 50 (20–90) | 0.003 |
| Baseline TLC (/mm3 ) | 12 [9–17] | 11 [8–15] | 0.33 |
| Final TLC (/mm3) | 6.3 [4.7–7.0] | 7.8 [6–9.9] | 0.003 |
Notes.
- Cr
- Creatinine
- ESR
- Erythrocyte sedimentation rate
- Hb
- Hemoglobin
- IE
- Infective endocarditis
- IV
- Intravenous
- TLC
- Total leucocytic count
Data presented as frequency (percentage) or median [25 th -75 th percentiles] as appropriate.